Revolution Medicines, Inc.(RVMD) Stock Research - Grey Stern Research
Loading...

Revolution Medicines, Inc. (RVMD) Stock Analysis

$39.41 (1.08%)

RVMD Financial Performance


Use the table below to view Revolution Medicines, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2023

Metric Value Ranking among Peers
Price $38.99 -
52 Week Low $15.44 -
52 Week High $40.21 -
Market Cap $6.4 Billion 2/16
Gross Margin -100% 16/16
Profit Margin -100% 10/16
EBITDA margin -21195% 16/16
Q3 - 2023 Revenue $742,000 9/16
Q3 - 2023 Earnings -$171.1 Million 16/16
Q3 - 2023 Free Cash Flow -$122.9 Million 16/16
Trailing 4 Quarters Revenue $26.9 Million 5/16
Trailing 4 Quarters Earnings -$384.4 Million 15/16
Quarterly Earnings Growth -133% 15/16
Annual Earnings Growth -50% 15/16
Quarterly Revenue Growth -78% 15/16
Annual Revenue Growth -12% 13/16
Cash On Hand $696.1 Million 1/16
Short Term Debt $7.4 Million 5/16
Long Term Debt $80.6 Million 3/16

Revolution Medicines, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Revolution Medicines, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/16
PS 239.05 2/16
PB 3.52 8/16
PC 9.24 8/16
Liabilities to Equity 0.13 15/16
ROA -0.19 1/16
ROE -0.21 1/16
Current Ratio 8.75 2/16
Quick Ratio 7.87 2/16
Long Term Debt to Equity 0.04 9/16
Debt to Equity 0.05 12/16
Burn Rate 3.95 3/16
Cash to Cap 0.11 9/16
CCR 0.72 8/16
EV to EBITDA -37.04 13/16
EV to Revenue 216.45 2/16

Company Details

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

CEO: Dr. Mark A. Goldsmith M.D., Ph.D.

Website: https://www.revmed.com

Address: 700 Saginaw Dr Redwood City, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Revolution Medicines, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Revolution Medicines, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Protagonist Therapeutics, Inc. PTGX $1.8 Billion
Blueprint Medicines Corporation BPMC $6.6 Billion
Agios Pharmaceuticals, Inc. AGIO $1.9 Billion
Atreca, Inc. BCEL $3.6 Million
Homology Medicines, Inc. FIXX $3.0 Million
Stoke Therapeutics, Inc. STOK $724.5 Million
TCR2 Therapeutics Inc. TCRR $58.1 Million
Black Diamond Therapeutics, Inc. BDTX $274.0 Million
Passage Bio, Inc. PASG $81.4 Million
Avidity Biosciences, Inc. RNA $2.8 Billion
Nurix Therapeutics, Inc. NRIX $984.1 Million
C4 Therapeutics, Inc. CCCC $390.8 Million
Kymera Therapeutics, Inc. KYMR $2.1 Billion
Sana Biotechnology, Inc. SANA $1.9 Billion
Monte Rosa Therapeutics, Inc. GLUE $262.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RVMD Income Statements
Quarter Year Revenue Earnings
Q3 2023 $ 742,000 -$171.1 Million
Q2 2023 $ 3.8 Million -$98.3 Million
Q1 2023 $ 7.0 Million -$58.5 Million
Q4 2022 $ 15.3 Million -$56.5 Million
Q3 2022 $ 3.4 Million -$73.3 Million
Q2 2022 $ 9.1 Million -$61.2 Million
Q1 2022 $ 7.6 Million -$57.6 Million
Q4 2021 $ 9.5 Million -$52.7 Million

View All

RVMD Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2023 $696.1 Million $2.1 Billion $87.9 Million $1.8 Billion
Q2 2023 $380.3 Million $1.1 Billion $63.3 Million $930.8 Million
Q1 2023 $427.2 Million $1.1 Billion $63.6 Million $952.2 Million
Q4 2022 $161.4 Million $811.9 Million $64.2 Million $685.2 Million
Q3 2022 $178.9 Million $825.9 Million $65.2 Million $681.4 Million
Q2 2022 $105.8 Million $632.8 Million $65.0 Million $498.8 Million
Q1 2022 $97.7 Million $682.8 Million $65.9 Million $551.0 Million
Q4 2021 $108.5 Million $738.0 Million $66.6 Million $602.6 Million

View All

RVMD Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2023 -$122.9 Million -$2.3 Million $338.4 Million
Q2 2023 -$68.2 Million -$1.1 Million -$46.0 Million
Q1 2023 -$64.1 Million -$1.8 Million $265.8 Million
Q4 2022 -$64.7 Million -$2.9 Million -$17.5 Million
Q3 2022 -$170.6 Million -$7.9 Million $73.2 Million
Q2 2022 -$115.3 Million -$4.4 Million $8.1 Million
Q1 2022 -$57.0 Million -$1.9 Million -$10.8 Million
Q4 2021 -$40.4 Million -$1.2 Million -$20.0 Million

View All